RT Journal Article
SR Electronic
T1 Identifying super-responders to benralizumab in severe asthma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3734
DO 10.1183/13993003.congress-2021.PA3734
VO 58
IS suppl 65
A1 David J Jackson
A1 Tim Harrison
A1 Francesco Menzella
A1 Vivian H Shih
A1 Annie Burden
A1 Esther Garcia Gil
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3734.abstract
AB Introduction: Severe eosinophilic asthma is increasingly recognised as a heterogeneous phenotype. Benralizumab has a unique ability to deplete blood and tissue eosinophils. Assessing clinical characteristics of patients who have a marked response to treatment (super-responders) can aid our understanding of severe asthma.Methods: ANDHI was a double-blind, placebo-controlled, 6-month study of patients with severe uncontrolled asthma and blood eosinophil levels (EOS) ≥150/µL. Rates and clinical characteristics of super-responders to benralizumab were evaluated (Table). View this table:Table. 1 Super-responder criteria*Results: Super-response was achieved in 53% of benralizumab and 35% of placebo patients (OR=2.14; p<0.0001) (Figure) and 60% of benralizumab patients with EOS ≥300/µL. Benralizumab super-responders had higher EOS (≥450/µL; 54% vs 27%), OCS use (23% vs 17%), adult-onset asthma (79% vs 62%), nasal polyposis (40% vs 27%), and less Phadiatop positivity (49% vs 65%) compared with non-super-responders. Conclusions: Certain clinical characteristics are associated with a dramatic response to benralizumab offering additional insights into the eosinophilic asthma phenotype.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3734.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).